Home
Market Commentary
Gold & Metals Exploration
Diamonds In Canada
Oil & Gas Review
High Tech Focus
Special Situations
Market Indices
Biotech
About Us
Subscribe
Contact Us


CURRENT ARTICLES
Send Page To a Friend | Friday July 30, 2010


ARCHIVE
read Allon Therapeutics Remains On-Track to Capitalize on an Unmet Multi-Billion Dollar Market for Alzheimer’s Disease and other Brain Illnesses
By Marc Davis, Managing Editor
November, 2007

Corporate Overview
Allon Therapeutics Inc. (TSX: NPC) is a Vancouver-based biotech pioneer in the development of proprietary drugs that combat some of society’s most pervasive neurodegenerative conditions, including Alzheimer's disease.

Most significantly, the company’s two leading multi-application in-development drugs (known as compounds) exhibit “blockbuster drug” potential – representing a prospective multi-billion dollar combined marketplace.


read SuperAntibodies Offer InNexus Biotechnology the Fast-Track to Multi-Billion Dollar Markets
By Justin Smallbridge and Marc Davis
February, 2005
InNexus Biotechnology Inc. (TSX V: IXS, NASD OTC BB: IXSBF) is a small but dynamic Canadian SuperAntibody developer that has made great strides since SmallCapMedia first began covering this story in early 2003.

read International Wex: Investment Opinion and Corporate Assessment Research Report
By Marc Davis - Managing Editor
August, 2004

Since we last covered International Wex Technologies Inc. in the fall of 2003, the company has made significant strides towards the commercialization of its inaugural pain management drug, Tectin ™ . Developed for the multi-billion dollar global cancer pain market, Tectin ™ clearly has the potential to make Wex a rising star in the biopharmaceutical sector within a few short years.   

read Positive Validation Trial Results Will Bring ProtoKinetix One Major Step Closer To the Multi-Billion Dollar Monoclonal Antibody Market
By Marc Davis, Managing Editor
April, 2004

SmallCapMedia has chosen ProtoKinetix Inc. (NASD-OTC.BB-PKTX) for special consideration from a number of companies involved in the research and development of anti-cancer treatments.


read On-Track To Develop The World's First SARS Vaccine, Sinovac Is A Success Story in the Making
By Marc Davis, Managing Editor
December, 2003
Another global outbreak of the deadly and highly infectious SARS virus could prove far more devastating than when it first appeared a year ago, scientists are now predicting. That is why the race is on to launch the world's first breakthrough vaccine as the initial line of defence against SARS (severe acute respiratory syndrome).

read International Wex Technologies Inc. Anticipates Positive Trial Results
By Marc Davis, Managing Editor
September, 2003

International Wex Technologies Inc. represents a good balance of risk and reward. This is especially the case with the imminent announcement of anticipated favorable pivotal Phase IIa Canadian clinical trial results for its inaugural drug, Tectin™. Accordingly, the commencement of a sustained uptrend in Wex’s share price is anticipated following this crucial milestone accomplishment.


read PharmaGap Unlocks Secrets Of Cellular Biology To Counteract Cancer And Other Deadly Diseases
By Marc Davis, Managing Editor
May, 2003

PharmaGap Inc. (TSX.V-GAP) (www.pharmagap.com ) is a small Canadian biomedical company that has pioneered a revolutionary approach to treating many forms of cancer and other serious diseases.


read InNexus Finds Fast Track To Capitalize On Multi-Billion Dollar "Monoclonal Antibody' Market
By Marc Davis, Managing Editor
January, 2003

The prospect of finding a cure for cancer and other pervasive life-threatening diseases may still be some years away. But recent medical breakthroughs in 'monoclonal antibody' genetic engineering are now making it possible for patients' immune systems to fight back, thereby improving their well-being and even extending life spans in many cases. Among the companies at the forefront of this new revolution in non-toxic, immune-system-boosting therapies is InNexus, Inc. This Seattle-based biotechnology company (which is being renamed InNexus Biotechnology Inc.) is soon to trade on Canada's TSX Venture Exchange under the symbol CUS, subject to a near-completed reverse take-over of an affiliated company.


Biotech news
 
 
  © 2005 SmallCapMedia.com - All Rights Reserved.